- Cassava Sciences, Inc. (SAVA) has been accused of data manipulation on its Alzheimer's therapeutic research by acknowledged short-sellers and scientists.
- As a pre-clinical company with no proven track record and "meme stock status," it is easy to see that SAVA is a good target for short sellers with "baseless" claims.
- The controversial US FDA approval for Biogen's Aduhelm does not help with the optics for any future Alzheimer's therapeutics as well, given CMS's stance on its reimbursement.
- The only way out is for SAVA to prove its efficacy through its Phase 3 clinical trials, though we expect more criticisms and volatility from the short sellers.
For further details see:
Why Are Short Sellers So Fascinated With Cassava Sciences?